Mitchell G. Lawrence
Papers
1
Total Citations
67
H-Index
1
About
Mitchell G. Lawrence is a leading figure in prostate cancer research, specializing in the development of preclinical models to accelerate drug discovery. His major contributions center on advancing three-dimensional (3D) organoid technologies, particularly through the use of patient-derived xenografts (PDXs). Lawrence’s most-cited work, a 2021 study on a high-throughput imaging assay for drug screening of 3D prostate cancer organoids (67 citations), addresses a critical bottleneck in the field: the scarcity of robust preclinical models for testing new therapies against advanced disease. By enabling scalable, high-content screening of candidate drugs on patient-relevant tissues, his research bridges the gap between laboratory discovery and clinical application. This innovative approach has been instrumental in expanding the repertoire of tools available for studying treatment-resistant prostate cancer. Lawrence’s work is widely recognized for its translational impact, providing a platform that not only improves the efficiency of drug testing but also enhances the fidelity of preclinical models to human disease. His contributions are shaping the future of personalized oncology, offering new hope for patients with limited treatment options.
Research Focus
Key Achievements
Top Papers
- 1